Urinary F2-Isoprostane Concentration as a Poor Prognostic Factor After Subarachnoid Hemorrhage.

Wiśniewski, Karol; Bieńkowski, Michał; Tomasik, Bartłomiej; Braun, Marcin; Bobeff, Ernest J.; Liberski, Paweł P.; Jaskólski, Dariusz J.

doi:10.1016/j.wneu.2017.07.145

Cited by 6 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pilot study, CSF F2-IsoP were positively correlated with poor outcome or severity of clinical condition [6]. In another small investigation, urinary levels of F2-IsoPs were associated with development of vasospasm and worse neurologic outcomes [5]. In contrast, we did not find any significant correlation between CSF F2-IsoPs and clinical outcomes of aneurysmal SAH.…”

Section: Discussioncontrasting

confidence: 78%

“…Previously, small studies had already identified elevation of F 2 -IsoP in serum, urine, and CSF following SAH and attempted correlations with clinical outcomes [5, 6]. In a pilot study, CSF F 2 -IsoP were positively correlated with poor outcome or severity of clinical condition [6].…”

Section: Discussionmentioning

confidence: 99%

“…Collectively, these compounds have emerged as one of the most reliable markers to assess oxidative stress in vivo, and given their procoagulant and vasospastic properties may potentially act as mediators of oxidative injury following SAH [4]. While previous studies have examined levels of F2-IsoPs and IsoF and their relationship to oxidative stress following SAH [5, 6, 7], their use as specific biomarkers for the development of DBI has not been explored to date.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Isofurans and isoprostanes as markers of delayed brain injury and mitochondrial dysfunction following aneurysmal subarachnoid hemorrhage. A prospective observational study

Gomes

Milne

Kallianpur

et al. 2021

Preprint

View full text Add to dashboard Cite

Introduction: F2-Isoprostanes (F2-IsoPs) and Isofurans (IsoF), specific markers of lipid peroxidation in vivo, have been reported to be elevated and have prognostic implications following subarachnoid hemorrhage (SAH). Platelet activation and vasoconstriction are attributed to these compounds. Elevated IsoF: F2-IsoPs ratios have been previously suggested as indicative of mitochondrial dysfunction. In this small study we examined their performance as specific biomarkers for delayed brain injury (DBI) development following SAH. We also explored if evidence of mitochondrial dysfunction could be found in a cohort of SAH patients. Methods: Eighteen patients with SAH and 7 controls with normal neuroimaging and CSF analysis results underwent CSF sampling and abstraction of clinical, demographic, and laboratory data. Samples (two) of CSF were collected on day 1 and once on days 5-8 post-bleed. F2-IsoP and IsoF assays were performed at Vanderbilt Eicosanoid Core Lab by gas chromatography/mass spectroscopy. Levels are expressed in median (IQR) for non-parametric data. Repeated sample measurement were compared using the Wilcoxon signed-rank test, whereas the Mann Whitney test was used for other non-parametric data. Results: Mean age was 61.2 + 15.7 (SAH cases) vs. 47.6 + 10 (controls) years, and 80% of SAH patients were female. Median Hunt-Hess score was 3 (2-4) and modified Fisher scale 3 (3-4). Thirty nine percent of patients developed DBI. F2-IsoP were significantly higher in SAH cases than in controls [47.5 (30.2-53.5) vs. 26.0 (21.2-34.5) pg/mL]. No significant differences were observed in patients with or without DBI [41 (33.5-52) vs. 44 (28.5-55.5) pg/mL]. IsoF were elevated in the second CSF sample in 9 patients, but undetectable in the remainder cases and all controls. Patients who developed DBI had significantly higher IsoF than cases who did not [(57 (34-72) vs. 0 (0-34) pg/mL]. Patients who met criteria for delayed injury had a significantly higher IsoF: F2IsoPs ratio on the late CSF sample [1.03 (1-1.38) vs. 0 (0-0.52)]. Conclusions: Preliminary findings from this study suggest that IsoF may represent a specific biomarker predicting DBI following SAH and provide possible evidence of CNS mitochondrial dysfunction in SAH. Future studies to further explore the value of IsoF as biomarkers of secondary brain injury and the contribution of mitochondrial dysfunction and ferroptosis to clinical outcomes following SAH seem warranted.

show abstract

Section: Discussioncontrasting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Isofurans and isoprostanes as markers of delayed brain injury and mitochondrial dysfunction following aneurysmal subarachnoid hemorrhage. A prospective observational study

Gomes

Milne

Kallianpur

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…P-selectin, a marker of endothelial activation, was found to have a significantly larger increase during DCI onset, compared to paired samples in the non-DCI group in two studies (17,18). F2-isoprostane in urine on day 3 after SAH was significantly associated with the occurrence of DCI in two studies (19,20). The quality of studies from which we found the seven validated biomarkers is listed in Table IV.…”

Section: Clinical DCImentioning

confidence: 96%

Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review

et al. 2023

View full text Add to dashboard Cite

Delayed cerebral ischemia (DCI) substantially contributes to disability and death in subarachnoid hemorrhage (SAH) patients; however, its pathophysiology is incompletely understood and diagnostic and therapeutic strategies are lacking. Biomarkers may help to elucidate the pathophysiology, optimize early diagnosis, or provide treatment targets. We systematically searched PubMed and Embase on October 13, 2021, for studies that evaluated at least one laboratory biomarker in patients with DCI, using the most up-to-date definition of DCI as proposed by a panel of experts in 2010. Quality of studies was assessed using the Newcastle-Ottawa Scale or Cochrane Collaboration’s risk of bias assessment tool. Biomarkers of clinical and radiological DCI were analyzed separately. Results were meta-analyzed if possible, otherwise narratively reviewed. Biomarkers were classified as significant, inconclusive, or nonsignificant. We defined validated biomarkers as those with significant results in meta-analyses, or in at least two studies using similar methodologies within the same time interval after SAH. The search yielded 209 articles with 724 different biomarkers; 166 studies evaluated 646 biomarkers of clinical DCI, of which 141 were significant and 7 were validated biomarkers (haptoglobulin 2-1 and 2-2, ADAMTS13, vWF, NLR, P-selectin, F2-isoprostane); 78 studies evaluated 165 biomarkers of radiological DCI, of which 63 were significant and 1 was a validated biomarker (LPR). Hence, this review provides a selection of seven biomarkers of clinical DCI and one biomarker of radiological DCI as most promising biomarkers of DCI. Future research should focus on determining the exact predictive, diagnostic, and therapeutic potentials of these biomarkers.

show abstract

Isofurans and Isoprostanes as Potential Markers of Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Observational Study

et al. 2021

View full text Add to dashboard Cite

Urinary F2-Isoprostane Concentration as a Poor Prognostic Factor After Subarachnoid Hemorrhage.

Cited by 6 publications

References 58 publications

Isofurans and isoprostanes as markers of delayed brain injury and mitochondrial dysfunction following aneurysmal subarachnoid hemorrhage. A prospective observational study

Isofurans and isoprostanes as markers of delayed brain injury and mitochondrial dysfunction following aneurysmal subarachnoid hemorrhage. A prospective observational study

Laboratory biomarkers of delayed cerebral ischemia following subarachnoid hemorrhage: A systematic review

Isofurans and Isoprostanes as Potential Markers of Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage: A Prospective Observational Study

Contact Info

Product

Resources

About